Results 11 to 20 of about 2,947 (138)

Evolution of ideas about the risk of tyramine syndrome developing during therapy with irreversible non-selective monoamine oxidase inhibitors (to the 70th anniversary of the first use of this group of antidepressants)

open access: yesНеврология, нейропсихиатрия, психосоматика, 2022
We describe the history of studying of the problem of tyramine syndrome during the treatment with antidepressants, irreversible non-selective monoamine oxidase inhibitors. Data on clinical observations are presented.
D. S. Danilov, M. Yu. Brovko
doaj   +1 more source

The History of Irreversible Non-Selective MAOI Antidepressants in Russia (for their 70th Anniversary)

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2023
The history of irreversible non-selective MAOI antidepressants in the USSR and Russia is systemized. The history of representatives’ appearance is described. The history of the study of pharmacological effects is highlighted.
D. S. Danilov
doaj   +1 more source

Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant Salmonella in A Serotype-Independent Manner

open access: yesPathogens, 2021
Non-typhoidal Salmonella ingeniously scavenges energy for growth from tyramine (TYR) and d-glucuronic acid (DGA), both of which occur in the host as the metabolic byproducts of the gut microbial metabolism. A critical first step in energy scavenging from
Raquel Burin, Devendra H. Shah
doaj   +1 more source

Clomipramine Induced Extrapyramidal Symptoms: A Case Series [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2023
Extra Pyramidal Symptoms (EPS) are a group of symptoms that include dystonia, bradykinesia, tremor, akathisia, and tardive dyskinesia. They are caused by the blockage of D2 receptors in the nigro-striatal pathway and the imbalanced acetyl choline ...
Disha Mukherjee   +2 more
doaj   +1 more source

Role of MAOI drugs as triggers of manic episodes in bipolar disorders: A case report and a narrative review

open access: yesEuropean Psychiatry, 2022
Introduction Use of Monoamine Oxidase Inhibitors (MAOIs) has experimented an important reduction in recent years, being replaced by other antidepressant drugs (ADs) associated with a better safety profile.
L. Olivier Mayorga   +5 more
doaj   +1 more source

A hypothesis for an alternative treatment for tobacco addiction: phenelzine, a monoamine oxidase inhibitor

open access: yesTobacco Induced Diseases, 2018
Background Current smoking cessation methods are primarily based on the theory that nicotine is the principal addicting compound overlooking the contribution of the monoamine oxidase inhibitors present in tobacco. Our study tests the hypothesis that the
Claude A. Curran   +4 more
doaj   +1 more source

Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer

open access: yesFrontiers in Immunology, 2019
Macrophages play an important role in regulating the tumor microenvironment (TME). Here we show that classical (M1) macrophage polarization reduced expression of LSD1, nuclear REST corepressor 1 (CoREST), and the zinc finger protein SNAIL.
Abel H. Y. Tan   +7 more
doaj   +1 more source

Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control

open access: yesPharmaceuticals, 2020
Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain and diabetic complications. The proposed mechanisms by which the atypical antipsychotic drug olanzapine increases body weight include central dysregulations leading to ...
Christian Carpéné   +8 more
doaj   +1 more source

Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity

open access: yesFrontiers in Genetics, 2021
Variability in the enzymatic activity of N-acetyltransferase 2 (NAT2) is an important contributor to interindividual differences in drug responses. However, there is little information on functional differences in N-acetylation activities according to ...
Koya Fukunaga   +8 more
doaj   +1 more source

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

open access: yesFrontiers in Pharmacology, 2023
Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely H3K4me1/2 and H3K9me1/2, using FAD as the cofactor.
Beatrice Noce   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy